IP Library › Granted Patent US 12,649,056
Granted Patent B2
US 12,649,056 · App. 16/166,957 · Granted Jun 9, 2026

Medical devices for treatment of cancer with electric fields

Inventors: Brian L. Schmidt (White Bear Lake, MN); Jacob M. Ludwig (Isanti, MN); Benjamin J. Haasl (Forest Lake, MN); Michael J. Kane (St. Paul, MN)
Assignee: Cardiac Pacemakers, Inc.
A61N1/36002A61N1/0408A61N1/0424A61N1/05A61N1/06A61N1/32A61N1/37247A61N1/36031A61N1/36132A61N1/37229
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,649,056
App. No.
16/166,957
Granted
Jun 9, 2026
Kind
B2
Abstract

Embodiments herein include medical devices and methods for using the same to treat cancerous tumors within a bodily tissue. In an embodiment, a medical device is included. The medical device can include an electric field generating circuit configured to generate one or more electric fields and control circuitry in communication with the electric field generating circuit. The control circuitry can be configured to control the generation of one or more electric fields from the electric field generating circuit. The control circuitry can cause the electric field generating circuit to deliver one or more electric fields at one or more frequencies selected from a range of between 10 kHz to 1 MHz to a cancerous tumor located within a bodily tissue. Other embodiments are also included herein.

Claims (15)

1 . A medical device comprising:

an electric field generating circuit configured to generate two or more electric fields; and

control circuitry in communication with the electric field generating circuit, the control circuitry configured to control delivery of the two or more electric fields from the electric field generating circuit; and

one or more leads in electrical communication with the electric field generating circuit, wherein each of the one or more leads comprise four or more electrodes disposed along a length of each of the one or more leads;

wherein the control circuitry causes the electric field generating circuit to generate the two or more electric fields at frequencies selected from a range of between 10 kHz to 1 MHz at a site of a cancerous tumor located within a bodily tissue, wherein the two or more electric fields are effective to prevent and/or disrupt cellular mitosis in a cancerous cell;

wherein the two or more electric fields are delivered along more than one vector between at least two pairs of the four or more electrodes surrounding the cancerous tumor, wherein a first pair of the four or more electrodes is positioned between a second pair of the four or more electrodes such that the second pair of the four or more electrodes has a broader electric field reach than the first pair of the four or more electrodes; and

wherein the control circuitry is further configured to generate the two or more electric fields having an electrical waveform alternating between positive pulses and negative pulses, the waveform including one or more OFF time periods between at least some adjacent positive and negative pulses, wherein the positive pulses and negative pulses are relative to a bias voltage between −5 V and 5 V and the one or more OFF time periods is defined by an electrical potential equal to the bias voltage.

2 . The medical device of claim 1 , wherein the electric field generating circuit generates the two or more electric fields at frequencies selected from a range of between 100 kHz to 300 kHz.

3 . The medical device of claim 1 , the medical device further comprising an electric field sensing circuit, the electric field sensing circuit comprising a first sensing electrode and a second sensing electrode, wherein the electric field sensing circuit is configured to measure an electrical potential difference between the first sensing electrode and the second sensing electrode.

4 . The medical device of claim 1 , wherein the control circuitry is further configured to generate the two or more electric fields with a waveform representing a superposition of at least two frequencies at least 10% different from one another.

5 . The medical device of claim 1 , wherein the control circuitry is further configured to generate the two or more electric fields by stepping through one or more frequencies, wherein stepping through the one or more frequencies includes a first predetermined dwell time at a first frequency, and a second predetermined dwell time at a second frequency.

6 . The medical device of claim 1 , wherein the control circuitry is further configured to generate the two or more electric fields having one or more programmable electric field strengths, wherein the one or more programmable electric field strengths are selected from a range of electric field strengths from 3 V/cm to 5 V/cm.

7 . The medical device of claim 1 , wherein the control circuitry is further configured to generate the two or more electric fields having two or more programmable electric field strengths and to alternate between generating electric field strengths of greater than 10 V/cm to generating electric field strengths of between 2 V/cm to 10 V/cm.

8 . The medical device of claim 1 , wherein the control circuitry is further configured to generate the two or more electric fields by sweeping through one or more electric fields comprising one or more electric field strengths, wherein sweeping through the two or more electric fields comprising one or more electric field strengths includes sweeping from a first electric field strength up to a second electric field strength and sweeping from the second electric field strength down to the first electric field strength, wherein the second electric field strength is higher than the first electric field strength.

9 . The medical device of claim 1 , wherein the control circuitry is further configured to generate the two or more electric fields by using a voltage control mode, the voltage control mode including modulating voltage in order to produce a desired electric field strength, or by using a current control mode, the current control mode including modulating current in order to produce a desired electric field strength, wherein the control circuit is further configured to adjust the current to maintain a substantially constant electric field strength.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2019
From: SCHMIDT, BRIAN L.; LUDWIG, JACOB M.; HAASL, BENJAMIN J.; KANE, MICHAEL J.
To: CARDIAC PACEMAKERS, INC.
Reel/Frame 047890/0383 →
Continuity (2)
Provisional Application 62575681 · Oct 23, 2017
Related Publication 20190117969A1 · Apr 25, 2019
References Cited (400)
US 4016886A · Doss et al. · 1977 [cited by applicant]
US 4369791A · Friedman · 1983 [cited by applicant]
US 5099838A · Bardy · 1992 [cited by applicant]
US 5113869A · Nappholz et al. · 1992 [cited by applicant]
US 5324328A · Li et al. · 1994 [cited by applicant]
US 5397342A · Heil, Jr. · 1995 [cited by examiner]
US 5458597A · Edwards et al. · 1995 [cited by applicant]
US 5582609A · Swanson · 1996 [cited by examiner]
US 5630426A · Eggers et al. · 1997 [cited by applicant]
US 5662698A · Altman et al. · 1997 [cited by applicant]
US 5834051A · Woloszko et al. · 1998 [cited by applicant]
US 5871530A · Williams et al. · 1999 [cited by applicant]
US 5971530A · Hashimoto · 1999 [cited by applicant]
US 6006755A · Edwards · 1999 [cited by applicant]
US 6366808B1 · Schroeppel et al. · 2002 [cited by applicant]
US 6569159B1 · Edwards et al. · 2003 [cited by applicant]
US 6673623B1 · Huberman · 2004 [cited by applicant]
US 6868289B2 · Palti · 2005 [cited by applicant]
US 6920361B2 · Williams · 2005 [cited by applicant]
US 7162310B2 · Doan · 2007 [cited by applicant]
US 7449021B2 · Underwood et al. · 2008 [cited by applicant]
US 7524274B2 · Patrick et al. · 2009 [cited by applicant]
US 7565205B2 · Palti · 2009 [cited by applicant]
US 7632235B1 · Karicherla et al. · 2009 [cited by applicant]
US 7656205B2 · Chen et al. · 2010 [cited by applicant]
US 7715921B2 · Palti · 2010 [cited by applicant]
US 7720549B2 · Schroeppel et al. · 2010 [cited by applicant]
US 7805201B2 · Palti · 2010 [cited by applicant]
US 7809441B2 · Kane · 2010 [cited by examiner]
US 7890183B2 · Palti et al. · 2011 [cited by applicant]
US 7917227B2 · Palti · 2011 [cited by applicant]
US 8002821B2 · Stinson · 2011 [cited by applicant]
US 8019414B2 · Palti · 2011 [cited by applicant]
US 8170648B2 · Field et al. · 2012 [cited by applicant]
US 8175698B2 · Palti et al. · 2012 [cited by applicant]
US 8229555B2 · Palti · 2012 [cited by applicant]
US RE43618E · Palti · 2012 [cited by applicant]
US 8244345B2 · Palti · 2012 [cited by applicant]
US 8262575B2 · Davies · 2012 [cited by applicant]
US 8406870B2 · Palti · 2013 [cited by applicant]
US 8447395B2 · Palti et al. · 2013 [cited by applicant]
US 8447396B2 · Palti et al. · 2013 [cited by applicant]
US 8465533B2 · Palti · 2013 [cited by applicant]
US 8483821B2 · Averina et al. · 2013 [cited by applicant]
US 8500713B2 · Ferek-Petric · 2013 [cited by applicant]
US 8706261B2 · Palti · 2014 [cited by applicant]
US 8715203B2 · Palti · 2014 [cited by applicant]
US 8718756B2 · Palti · 2014 [cited by applicant]
US 8764675B2 · Palti · 2014 [cited by applicant]
US 8805466B2 · Salahieh et al. · 2014 [cited by applicant]
US 8956352B2 · Mauch et al. · 2015 [cited by applicant]
US 9005100B2 · Gnanashanmugam et al. · 2015 [cited by applicant]
US 9023090B2 · Palti · 2015 [cited by applicant]
US 9023091B2 · Palti · 2015 [cited by applicant]
US 9039674B2 · Palti et al. · 2015 [cited by applicant]
US 9056203B2 · Palti et al. · 2015 [cited by applicant]
US 9179974B2 · Ku et al. · 2015 [cited by applicant]
US 9248278B2 · Crosby et al. · 2016 [cited by applicant]
US 9283383B2 · Osypka · 2016 [cited by examiner]
US 9308039B2 · Azure · 2016 [cited by applicant]
US 9387323B2 · Fleischhacker et al. · 2016 [cited by applicant]
US 9427278B2 · Swanson · 2016 [cited by applicant]
US 9440068B2 · Palti et al. · 2016 [cited by applicant]
US 9474486B2 · Eliason et al. · 2016 [cited by applicant]
US 9526911B1 · Azure et al. · 2016 [cited by applicant]
US 9630022B2 · Bourke et al. · 2017 [cited by applicant]
US 9655669B2 · Palti et al. · 2017 [cited by applicant]
US 9750934B2 · Palti et al. · 2017 [cited by applicant]
US 9833617B2 · Travers et al. · 2017 [cited by applicant]
US 9877781B2 · Grasse et al. · 2018 [cited by applicant]
US 9910453B2 · Wasserman et al. · 2018 [cited by applicant]
US 10029117B2 · Bourke · 2018 [cited by applicant]
US 10238862B2 · Cook et al. · 2019 [cited by applicant]
US 10265530B1 · Perryman et al. · 2019 [cited by applicant]
US 10376177B2 · Valvano et al. · 2019 [cited by applicant]
US 10471254B2 · Sano et al. · 2019 [cited by applicant]
US 10849675B2 · Wallace · 2020 [cited by applicant]
US 11191956B2 · Giladi et al. · 2021 [cited by applicant]
US 11331493B2 · Pivonka et al. · 2022 [cited by applicant]
US 11338135B2 · Schmidt et al. · 2022 [cited by applicant]
US 11420049B2 · Schmidt et al. · 2022 [cited by applicant]
US 11607542B2 · Schmidt et al. · 2023 [cited by applicant]
US 11691006B2 · Schmidt et al. · 2023 [cited by applicant]
US 11712561B2 · Schmidt et al. · 2023 [cited by applicant]
US 11850422B2 · Schmidt et al. · 2023 [cited by applicant]
US 11883655B2 · Srivastava et al. · 2024 [cited by applicant]
US 12109412B2 · Schmidt et al. · 2024 [cited by applicant]
US 12186553B2 · Schmidt et al. · 2025 [cited by applicant]
US 12403306B2 · Schmidt et al. · 2025 [cited by applicant]
US 20010044643A1 · Litovitz · 2001 [cited by applicant]
US 20020026183A1 · Simpson · 2002 [cited by applicant]
US 20020049485A1 · Smits · 2002 [cited by applicant]
US 20020065544A1 · Smits · 2002 [cited by applicant]
US 20030020416A1 · Kobayashi · 2003 [cited by applicant]
US 20030069623A1 · Stypulkowski · 2003 [cited by applicant]
US 20030204161A1 · Ferek-Petric · 2003 [cited by applicant]
US 20040010290A1 · Schroeppel · 2004 [cited by examiner]
US 20040010303A1 · Bolea et al. · 2004 [cited by applicant]
US 20040147969A1 · Mann et al. · 2004 [cited by applicant]
US 20040162600A1 · Williams · 2004 [cited by applicant]
US 20040176804A1 · Palti · 2004 [cited by applicant]
US 20040215235A1 · Jackson et al. · 2004 [cited by applicant]
US 20040215296A1 · Ganz et al. · 2004 [cited by applicant]
US 20050004507A1 · Schroeppel · 2005 [cited by examiner]
US 20050043894A1 · Fernandez · 2005 [cited by applicant]
US 20050096584A1 · Ferek-Petric · 2005 [cited by examiner]
US 20050222623A1 · Kroll et al. · 2005 [cited by applicant]
US 20050222646A1 · Kroll · 2005 [cited by examiner]
US 20050240173A1 · Palti · 2005 [cited by applicant]
US 20050288730A1 · Deem et al. · 2005 [cited by applicant]
US 20050288761A1 · Brabec et al. · 2005 [cited by applicant]
US 20060024802A1 · Muller et al. · 2006 [cited by applicant]
US 20060149341A1 · Palti · 2006 [cited by applicant]
US 20060190053A1 · Dobak, III · 2006 [cited by examiner]
US 20060259092A1 · Spadgenske et al. · 2006 [cited by applicant]
US 20060259099A1 · Goetz et al. · 2006 [cited by applicant]
US 20060282122A1 · Palti · 2006 [cited by applicant]
US 20060282126A1 · Fischbach et al. · 2006 [cited by applicant]
US 20070033660A1 · Palti · 2007 [cited by applicant]
US 20070135861A1 · Wallace et al. · 2007 [cited by applicant]
US 20070179550A1 · Dennis et al. · 2007 [cited by applicant]
US 20070225766A1 · Palti · 2007 [cited by applicant]
US 20070239213A1 · Palti · 2007 [cited by applicant]
US 20070239244A1 · Morgan · 2007 [cited by examiner]
US 20070255340A1 · Giftakis et al. · 2007 [cited by applicant]
US 20070270675A1 · Kane et al. · 2007 [cited by applicant]
US 20070270916A1 · Fischell et al. · 2007 [cited by applicant]
US 20080058669A1 · Kroll · 2008 [cited by applicant]
US 20080058887A1 · Griffin et al. · 2008 [cited by applicant]
US 20080071265A1 · Azure · 2008 [cited by applicant]
US 20080071350A1 · Stinson et al. · 2008 [cited by applicant]
US 20080086073A1 · Mcdaniel · 2008 [cited by applicant]
US 20080097424A1 · Wizeman et al. · 2008 [cited by applicant]
US 20080154346A1 · Smith · 2008 [cited by examiner]
US 20080172116A1 · Mrva et al. · 2008 [cited by applicant]
US 20080195227A1 · Boling et al. · 2008 [cited by applicant]
US 20080208271A1 · Sih et al. · 2008 [cited by applicant]
US 20080275524A1 · Furness et al. · 2008 [cited by applicant]
US 20090076500A1 · Azure et al. · 2009 [cited by applicant]
US 20090192381A1 · Brockway · 2009 [cited by examiner]
US 20090234211A1 · Li · 2009 [cited by examiner]
US 20100016936A1 · Stevenson · 2010 [cited by examiner]
US 20100168820A1 · Maniak et al. · 2010 [cited by applicant]
US 20100191311A1 · Scheiner et al. · 2010 [cited by applicant]
US 20100198298A1 · Schulman et al. · 2010 [cited by applicant]
US 20100217356A1 · Bikson et al. · 2010 [cited by applicant]
US 20100261994A1 · Davalos · 2010 [cited by examiner]
US 20100298895A1 · Ghaffari et al. · 2010 [cited by applicant]
US 20100331938A1 · Sommer et al. · 2010 [cited by applicant]
US 20110071608A1 · Fleischhacker et al. · 2011 [cited by applicant]
US 20110077717A1 · Poletto · 2011 [cited by examiner]
US 20110125215A1 · Goetz et al. · 2011 [cited by applicant]
US 20110137229A1 · Palti et al. · 2011 [cited by applicant]
US 20110224665A1 · Crosby et al. · 2011 [cited by applicant]
US 20110238057A1 · Moss et al. · 2011 [cited by applicant]
US 20110306878A1 · Desimone · 2011 [cited by examiner]
US 20120035616A1 · Olsen et al. · 2012 [cited by applicant]
US 20120130444A1 · Wei et al. · 2012 [cited by applicant]
US 20120158072A1 · Venook et al. · 2012 [cited by applicant]
US 20120158122A1 · Mattson et al. · 2012 [cited by applicant]
US 20120203307A1 · Schroeppel et al. · 2012 [cited by applicant]
US 20120232615A1 · Barolat et al. · 2012 [cited by applicant]
US 20120283726A1 · Palti · 2012 [cited by examiner]
US 20130023946A1 · Valvano et al. · 2013 [cited by applicant]
US 20130165916A1 · Mathur et al. · 2013 [cited by applicant]
US 20130204068A1 · Gnanashanmugam et al. · 2013 [cited by applicant]
US 20130261706A1 · Mirro · 2013 [cited by examiner]
US 20130261711A1 · Sivo · 2013 [cited by applicant]
US 20130289649A1 · Averina et al. · 2013 [cited by applicant]
US 20130289664A1 · Johanek · 2013 [cited by applicant]
US 20130310898A1 · Ollivier et al. · 2013 [cited by applicant]
US 20140005753A1 · Carbunaru · 2014 [cited by examiner]
US 20140052227A1 · Wahlstrand et al. · 2014 [cited by applicant]
US 20140094888A1 · True et al. · 2014 [cited by applicant]
US 20140107511A1 · Banet et al. · 2014 [cited by applicant]
US 20140142670A1 · Radhakrishnan et al. · 2014 [cited by applicant]
US 20140276781A1 · Beani et al. · 2014 [cited by applicant]
US 20140276811A1 · Koblish et al. · 2014 [cited by applicant]
US 20140350541A1 · Hill et al. · 2014 [cited by applicant]
US 20140350653A1 · Shiroff et al. · 2014 [cited by applicant]
US 20150005804A1 · Franano et al. · 2015 [cited by applicant]
US 20150066024A1 · Azure · 2015 [cited by applicant]
US 20150119952A1 · Sharma · 2015 [cited by examiner]
US 20150134022A1 · Lee et al. · 2015 [cited by applicant]
US 20150180161A1 · Olson et al. · 2015 [cited by applicant]
US 20150182282A1 · Zemel et al. · 2015 [cited by applicant]
US 20150320995A1 · Nazareth et al. · 2015 [cited by applicant]
US 20150321000A1 · Rosenbluth et al. · 2015 [cited by applicant]
US 20150353916A1 · Subramaniam · 2015 [cited by examiner]
US 20150374992A1 · Crosby et al. · 2015 [cited by applicant]
US 20160022986A1 · Travers · 2016 [cited by examiner]
US 20160029960A1 · Toth et al. · 2016 [cited by applicant]
US 20160068598A1 · Yan et al. · 2016 [cited by applicant]
US 20160082258A1 · Kramer et al. · 2016 [cited by applicant]
US 20160121106A1 · Marshall et al. · 2016 [cited by applicant]
US 20160128767A1 · Azamian et al. · 2016 [cited by applicant]
US 20160129276A1 · Fried et al. · 2016 [cited by applicant]
US 20160175580A1 · Marshall et al. · 2016 [cited by applicant]
US 20160250476A1 · Kaemmerer et al. · 2016 [cited by applicant]
US 20160250483A1 · Klimovitch et al. · 2016 [cited by applicant]
US 20160278863A1 · Arai et al. · 2016 [cited by applicant]
US 20160331459A1 · Townley · 2016 [cited by examiner]
US 20160346536A1 · Palti et al. · 2016 [cited by applicant]
US 20170007310A1 · Rajagopalan et al. · 2017 [cited by applicant]
US 20170035496A1 · Nagale et al. · 2017 [cited by applicant]
US 20170049514A1 · Cosman · 2017 [cited by applicant]
US 20170065339A1 · Mickelsen · 2017 [cited by applicant]
US 20170105793A1 · Cao et al. · 2017 [cited by applicant]
US 20170120041A1 · Wenger et al. · 2017 [cited by applicant]
US 20170173340A1 · Gupte et al. · 2017 [cited by applicant]
US 20170189098A1 · Azure et al. · 2017 [cited by applicant]
US 20170209691A1 · Sorajja · 2017 [cited by applicant]
US 20170215939A1 · Palti · 2017 [cited by examiner]
US 20170231694A1 · Mathur et al. · 2017 [cited by applicant]
US 20170251976A1 · Schouenborg · 2017 [cited by applicant]
US 20170266371A1 · Leonhardt · 2017 [cited by examiner]
US 20170281934A1 · Giladi · 2017 [cited by examiner]
US 20170281955A1 · Maile · 2017 [cited by examiner]
US 20170312501A1 · Bornzin · 2017 [cited by examiner]
US 20170333702A1 · Barner · 2017 [cited by applicant]
US 20180001075A1 · Kirson et al. · 2018 [cited by applicant]
US 20180001078A1 · Kirson et al. · 2018 [cited by applicant]
US 20180008708A1 · Giladi et al. · 2018 [cited by applicant]
US 20180021563A1 · Van De Stolpe et al. · 2018 [cited by applicant]
US 20180050200A1 · Wasserman et al. · 2018 [cited by applicant]
US 20180104486A1 · Yoon · 2018 [cited by examiner]
US 20180110978A1 · Beebe · 2018 [cited by examiner]
US 20180154142A1 · Guo et al. · 2018 [cited by applicant]
US 20180221088A1 · Govari et al. · 2018 [cited by applicant]
US 20180246079A1 · Wang et al. · 2018 [cited by applicant]
US 20180256906A1 · Pivonka et al. · 2018 [cited by applicant]
US 20180289954A1 · Hebb et al. · 2018 [cited by applicant]
US 20190008555A1 · O'Mahony · 2019 [cited by applicant]
US 20190117962A1 · Chiang et al. · 2019 [cited by applicant]
US 20190117970A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190117971A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190117972A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190117973A1 · Schmidt et al. · 2019 [cited by applicant]
US 20190255344A1 · Carter · 2019 [cited by examiner]
US 20190262605A1 · Babakhani et al. · 2019 [cited by applicant]
US 20190321624A1 · De Kock et al. · 2019 [cited by applicant]
US 20190343398A1 · Zimmer · 2019 [cited by applicant]
US 20200009377A1 · Chang et al. · 2020 [cited by applicant]
US 20200061385A1 · Schwarz et al. · 2020 [cited by applicant]
US 20200197086A1 · Azamian et al. · 2020 [cited by applicant]
US 20200330756A1 · Schmidt et al. · 2020 [cited by applicant]
US 20200330757A1 · Schmidt et al. · 2020 [cited by applicant]
US 20200330758A1 · Schmidt et al. · 2020 [cited by applicant]
US 20200338344A1 · Schmidt et al. · 2020 [cited by applicant]
US 20200338345A1 · Schmidt et al. · 2020 [cited by applicant]
US 20200338346A1 · Schmidt et al. · 2020 [cited by applicant]
US 20210260370A1 · Srivastava et al. · 2021 [cited by applicant]
US 20210339015A1 · Dinsmoor et al. · 2021 [cited by applicant]
US 20220241586A1 · Spehr et al. · 2022 [cited by applicant]
US 20220288388A1 · Rondoni et al. · 2022 [cited by applicant]
US 20220296907A1 · Schmidt et al. · 2022 [cited by applicant]
US 20230218894A1 · Arnholt et al. · 2023 [cited by applicant]
US 20230330416A1 · Schmidt et al. · 2023 [cited by applicant]
US 20240024670A1 · Schmidt et al. · 2024 [cited by applicant]
US 20240115856A1 · Schmidt et al. · 2024 [cited by applicant]
US 20240226547A1 · Schmidt et al. · 2024 [cited by applicant]
US 20250099752A1 · Schmidt et al. · 2025 [cited by applicant]
US 20250345603A1 · Schmidt et al. · 2025 [cited by applicant]
AU 2005301103 · 2006 [cited by applicant]
CN 1561925 · 2005 [cited by applicant]
CN 101693875 · 2010 [cited by applicant]
CN 202365923 · 2012 [cited by applicant]
CN 202844368 · 2013 [cited by applicant]
CN 104955386 · 2015 [cited by applicant]
CN 204698678 · 2015 [cited by applicant]
CN 106823145 · 2017 [cited by applicant]
CN 111278504 · 2025 [cited by applicant]
CN 113766948 · 2025 [cited by applicant]
EP 2942023 · 2015 [cited by applicant]
EP 3700626 · 2024 [cited by applicant]
EP 4445943 · 2024 [cited by applicant]
EP 4480526 · 2024 [cited by applicant]
JP 2011030734 · 2011 [cited by applicant]
TW 201039699 · 2010 [cited by applicant]
WO 9513113 · 1995 [cited by applicant]
WO 9526911 · 1995 [cited by applicant]
WO 9639966 · 1996 [cited by applicant]
WO 0158371 · 2001 [cited by applicant]
WO 0167098 · 2001 [cited by applicant]
WO 2006047833 · 2006 [cited by applicant]
WO 2008089360 · 2008 [cited by applicant]
WO 2009036457 · 2009 [cited by applicant]
WO 2009036459 · 2009 [cited by applicant]
WO 2013052590 · 2013 [cited by applicant]
WO 2014114433 · 2014 [cited by applicant]
WO 2015100451 · 2015 [cited by applicant]
WO 2015175570 · 2015 [cited by applicant]
WO 2016065263 · 2016 [cited by applicant]
WO 2016168485 · 2016 [cited by applicant]
WO 2016179712 · 2016 [cited by applicant]
WO 2016199142 · 2016 [cited by applicant]
WO 2017123981 · 2017 [cited by applicant]
WO 2018207103 · 2018 [cited by applicant]
WO 2019084011 · 2019 [cited by applicant]
WO 2023137008 · 2023 [cited by applicant]
Giladi, M., Schneiderman, R., Voloshin, T. et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. Sci Rep 5, 18046 (2016) (Year… [cited by examiner]
International Search Report and Written Opinion for PCT Application No. PCT/US2018/057104 mailed Dec. 20, 2018 (14 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2018/057115 mailed Jan. 4, 2019 (13 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2018/057120 mailed Dec. 19, 2018 (14 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2018/057127 mailed Jan. 18, 2019 (12 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2018/057117 mailed Dec. 20, 2018 (14 pages). [cited by applicant]
Di Sebastiano, Andrea R. et al., “Preclinical Outcomes of Intratumoral Modulation Therapy for Glioblastoma,” Scientific Reports (2018) 8:7301 (11 pages). [cited by applicant]
Xu, Hu et al., “In Vitro Validation of Intratumoral Modulation Therapy for Glioblastoma,” Anticancer Research 36:71-80 (2016), 10 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2018/057104 mailed May 7, 2020 (8 pages). [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2018/057115 mailed May 7, 2020 (9 pages). [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2018/057117 mailed May 7, 2020 (8 pages). [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2018/057120 mailed May 7, 2020 (8 pages). [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2018/057127 mailed May 7, 2020 (8 pages). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/167,140 mailed Apr. 6, 2020 (28 pages). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/167,079 mailed Apr. 17, 2020 (36 pages). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/167,087 mailed May 27, 2020 (31 pages). [cited by applicant]
Response to Non-Final Rejection mailed on Apr. 17, 2020 for U.S. Appl. No. 16/167,079, submitted via EFS-Web on Jul. 7, 2020, 17 pages. [cited by applicant]
Response to Non-Final Rejection mailed on Apr. 6, 2020 for U.S. Appl. No. 16/167,140, submitted via EFS-Web on Jul. 6, 2020, 12 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2020/028508 mailed Aug. 3, 2020 (13 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2020/028509 mailed Jun. 30, 2020 (15 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2020/028512 mailed Jul. 13, 2020 (14 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2020/029270 mailed Oct. 26, 2020 (19 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2020/029274 mailed Aug. 28, 2020 (19 pages). [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2020/029277 mailed Jul. 13, 2020 (15 pages). [cited by applicant]
Invitation to Pay Additional Fees for PCT Application No. PCT/US2020/029270 mailed Aug. 28, 2020 (14 pages). [cited by applicant]
Invitation to Pay Additional Fees for PCT Application No. PCT/US2020/029274 mailed Jul. 7, 2020 (13 pages). [cited by applicant]
Kirson, Eilon D. et al., “Disruption of Cancer Cell Replication by Alternating Electric Fields,” Cancer Research 64, 3288-3295, May 1, 2004 (8 pages). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/167,079 mailed Jan. 6, 2021 (28 pages). [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC for European Patent Application No. 18800411.3 filed Dec. 9, 2020 (11 pages). [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC for European Patent Application No. 18801134.0 filed Dec. 11, 2020 (9 pages). [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC for European Patent Application No. 18801136.5 filed Dec. 10, 2020 (8 pages). [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC for European Patent Application No. 18801137.3 filed Dec. 10, 2020 (7 pages). [cited by applicant]
Response to Communication Pursuant to Rules 161(1) and 162 EPC for European Patent Application No. 18801138.1 filed Dec. 11, 2020 (16 pages). [cited by applicant]
Response to Examination Report for Australian Patent Application No. 2018354149 filed Dec. 21, 2020 (14 pages). [cited by applicant]
Response to Examination Report for Australian Patent Application No. 2018354157 filed Dec. 31, 2020 (17 pages). [cited by applicant]
Response to Examination Report for Australian Patent Application No. 2018354159 filed Jan. 18, 2021 (21 pages). [cited by applicant]
Response to Final Rejection mailed on Oct. 13, 2020 for U.S. Appl. No. 16/167,087, 11 pages, submitted via EFS-Web on Jan. 13, 2021. [cited by applicant]
Response to Final Rejection mailed on Oct. 19, 2020 for U.S. Appl. No. 16/167,140, submitted via EFS-Web on Jan. 19, 2021, 16 pages. [cited by applicant]
Response to Non-Final Rejection mailed on Oct. 7, 2020 for U.S. Appl. No. 16/167,116, submitted via EFS-Web on Jan. 6, 2021, 13 pages. [cited by applicant]
Second Examination Report for Australian Patent Application No. 2018354149 mailed Jan. 8, 2021 (4 pages). [cited by applicant]
Final Office Action for U.S. Appl. No. 16/167,116 mailed Jan. 21, 2021 (25 pages). [cited by applicant]
Final Office Action for U.S. Appl. No. 16/167,079 mailed Sep. 15, 2020 (27 pages). [cited by applicant]
Final Office Action for U.S. Appl. No. 16/167,087 mailed Oct. 13, 2020 (21 pages). [cited by applicant]
Final Office Action for U.S. Appl. No. 16/167,140 mailed Oct. 19, 2020 (27 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2018354149 mailed Jul. 29, 2020 (5 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2018354157 mailed Jul. 31, 2020 (5 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2018354159 mailed Aug. 12, 2020 (5 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2018354162 mailed Sep. 29, 2020 (8 pages). [cited by applicant]
First Examination Report for Australian Patent Application No. 2018354167 mailed Sep. 14, 2020 (5 pages). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/167,116 mailed Oct. 7, 2020 (40 pages). [cited by applicant]
Response to Final Rejection mailed on Sep. 15, 2020 for U.S. Appl. No. 16/167,079, submitted via EFS-Web on Nov. 5, 2020, 20 pages. [cited by applicant]
Response to Non-Final Rejection mailed on May 27, 2020 for U.S. Appl. No. 16/167,087, submitted via EFS-Web on Aug. 20, 2020, 10 pages. [cited by applicant]
Wang, Lijun et al., “Tumour Cell Membrane Poration and Ablation by Pulsed Low-Intensity Electric Field with Carbon Nanotubes,” Int. J. Mol. Sci. 2015, 16, 6890-6901 (12 pages). [cited by applicant]
“Optune®—Elevate Expectations / Patient Information and Operation Manual,” Novocure™, www.optune.com, 46, pages, Jan. 2019. [cited by applicant]
Novocure Announces Launch of the inovitro™ Laboratory Research System, Press Release, 2 pages, Nov. 21, 2013. [cited by applicant]
Communication Pursuant to Article 94(3) EPC for European Patent Application No. 18801137.3 mailed Mar. 5, 2021 (4 pages). [cited by applicant]
Examination Report for Australian Patent Application No. 2018354162 mailed Feb. 4, 2021 (5 pages). [cited by applicant]
Office Action for Japanese Patent Application No. 2020-542718 mailed Feb. 9, 2021 11 pages) with English Translation. [cited by applicant]
Office Action for Japanese Patent Application No. 2020-542721 mailed Feb. 9, 2021 (5 pages) No. English Translation. [cited by applicant]
Office Action for Japanese Patent Application No. 2020-542722 mailed Feb. 9, 2021 (5 pages) with English Summary. [cited by applicant]
Response to Examination Report for Australian Patent Application No. 2018354162 filed Jan. 28, 2021 (15 pages). [cited by applicant]
Response to Examination Report for Australian Patent Application No. 2018354167 filed Jan. 28, 2021 (17 pages). [cited by applicant]
Response to Final Rejection mailed on Jan. 21, 2021 for U.S. Appl. No. 16/167,116, submitted via EFS-Web on Mar. 2, 2021, 12 pages. [cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 18801138.1 mailed Jun. 7, 2021 (7 pages). [cited by applicant]
“Examination Report,” for Australian Patent Application No. 2018354162 mailed Apr. 21, 2021 (5 pages). [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 16/167,079 mailed Jun. 23, 2021 (34 pages). [cited by applicant]
“First Office Action,” for Chinese Patent Application No. 201880068896.3 mailed Apr. 13, 2021 (17 pages) with English Summary. [cited by applicant]
“International Search Report and Written Opinion,” for PCT Application No. PCT/US2021/019160 mailed Jun. 2, 2021 (15 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/167,087 mailed Mar. 31, 2021 (28 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/855,421 mailed May 28, 2021 (37 pages). [cited by applicant]
“Office Action,” for Canadian Patent Application No. 3,079,289 mailed May 28, 2021 (4 pages). [cited by applicant]
“Response to Examination Report,” for Australian Patent Application No. 2018354162 filed Mar. 30, 2021 (15 pages). [cited by applicant]
“Response to Non-Final Rejection,” mailed on Jan. 6, 2021 for U.S. Appl. No. 16/267,079, submitted via EFS-Web on Apr. 6, 2021, 19 pages. [cited by applicant]
“Response to Non-Final Rejection,” mailed on Mar. 31, 2021 for U.S. Appl. No. 16/167,087, submitted via EFS-Web on Jun. 23, 2021, 12 pages. [cited by applicant]
“Response to Second Examination Report,” for Australian Patent Application No. 2018354149 filed Apr. 13, 2021 (19 pages). [cited by applicant]
“Office Action,” for Japanese Patent Application No. 2020-542719 mailed Jun. 1, 2021 (9 pages) with English Translation. [cited by applicant]
“Office Action,” for Japanese Patent Application No. 2020-542720 mailed May 11, 2021 (13 pages) with English Translation. [cited by applicant]
“Examination Report,” for Canadian Patent Application No. 3,079,213 mailed Jul. 12, 2021 (4 pages). [cited by applicant]
“Examination Report,” for Canadian Patent Application No. 3,079,282 mailed Jul. 14, 2021 (4 pages). [cited by applicant]
“Examination Report,” for Canadian Patent Application No. 3,079,314 mailed Jul. 14, 2021 (4 pages). [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 16/167,087mailed Aug. 2, 2021 (25 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/167,116 mailed Sep. 3, 2021 (29 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/167,140 mailed Jul. 12, 2021 (32 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/850,720 mailed Aug. 24, 2021 (32 pages). [cited by applicant]
“Non-Final Office Action,” for U.S. Appl. No. 16/855,433 mailed Sep. 8, 2021 (32 pages). [cited by applicant]
“Response to Examination Report,” for Australian Patent Application No. 2018354162 filed Jul. 13, 2021 (18 pages). [cited by applicant]
“Response to Final Rejection,” mailed on Jun. 23, 2021 for U.S. Appl. No. 16/167,079, submitted via EFS-Web on Sep. 9, 2021, 16 pages. [cited by applicant]
“Response to Non-Final Rejection,” mailed on May 28, 2021 for U.S. Appl. No. 16/855,421, submitted via EFS-Web on Aug. 20, 2021, 11 pages. [cited by applicant]
“Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 18801137.3 mailed Sep. 15, 2021 (4 pages). [cited by applicant]
“First Office Action,” for Chinese Patent Application No. 201880078117.8 mailed Jul. 20, 2021 (14 pages) with English Summary. [cited by applicant]
“Response to Communication Pursuant to Article 94(3) EPC,” for European Patent Application No. 18801138.1 filed Oct. 15, 2021 (10 pages). [cited by applicant]
“Response to Non-Final Rejection,” mailed on Jul. 12, 2021 for U.S. Appl. No. 16/167,140, submitted via EFS-Web on Oct. 12, 2021, 16 pages. [cited by applicant]
“Response to Office Action,” for Canadian Patent Application No. 3,079,289 filed with CIPO Sep. 23, 2021 (17 pages). [cited by applicant]
“Decision of Rejection,” for Japanese Patent Application No. 2020-542719 mailed Oct. 19, 2021 (3 pages) No. English Translation. [cited by applicant]
“Final Office Action,” for U.S. Appl. No. 16/855,421 mailed Nov. 5, 2021 (25 pages). [cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2020/028508 mailed Nov. 4, 2021 (8 pages). [cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2020/028509 mailed Nov. 4, 2021 (9 pages). [cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2020/028512 mailed Nov. 4, 2021 (8 pages). [cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2020/029270 mailed Nov. 4, 2021 (11 pages). [cited by applicant]
“International Preliminary Report on Patentability,” for PCT Application No. PCT/US2020/029274 mailed Nov. 4, 2021 (13 pages). [cited by applicant]